HYALF news!
biz.yahoo.com
Thursday May 14, 10:17 am Eastern Time
Company Press Release
SOURCE: Hyal Pharmaceutical Corporation
Hyal Appoints Two New Directors
MISSISSAUGA, Ont., May 14 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM:HYALF - news;
TSE:HPC - news) is pleased to announce the appointment of Dr. George A. deVeber and Dr. Jan Oudenes to the Board of
Directors of the Corporation.
Dr. deVeber is a prominent Canadian nephrologist and biotechnology consultant who initiated and led the Dialysis and
Transplantation program at Toronto's Western Hospital. A well-known consultant in the areas of thcare, biotechnology and
government affairs, he is currently the Medical Director of Vasogen, Inc. Dr. deVeber is a former Vice President, Medical
Affairs of Baxter Corporation, and a past President of the Canadian Transplantation Society and the Ontario branch of the
Kidney Foundation of Canada.
Dr. Oudenes is a well-known scientist in the field of synthetic organic chemistry and pharmaceutical chemistry. For the past
decade, he has been President of Torcan Chemical Ltd., a research, development and manufacturing company of new chemical
entities and active pharmaceutical ingredients, based in Aurora, Ontario. Dr. Oudenes studied in The Netherlands, Canada and
Switzerland, and has published extensively in scientific and patent literature.
Hyal Pharmaceutical Corporation is a drug delivery company engaged in research and development and is seeking worldwide
commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronan Induced Targeting Technology (HIT)(TM)
and Hyaluronan Improved Liposome Technology (HILT)(TM).
SOURCE: Hyal Pharmaceutical Corporation
More Quotes and News:
Hyal Pharmaceutical Corp (Toronto:HPC.TO - news; Toronto:HPC.TO - news;
Nasdaq:HYALF - news)
Related News Categories: medical/pharmaceutical |
